SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
ALT

Altimmune, Inc. (NASDAQ:ALT)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$1.33-$0.08 (-5.67%)
 
Market cap
$259M
Insider Score
Health Score
Analyst consensus
Listed since
May 26, 2017
Market Cap$258.80M-72.3%
Revenue (ttm)$26.00K+30.0%
Net Income-$104.35M-24.4%
EPS-$0.72+32.7%
Shares Out194.59M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend DateFeb 6, 2017
Volume4,019,048
Open$1.39
Previous Close$1.41
Day's Range$1.32 - $1.46
52-Week Range$1.32 - $6.44
Beta0.18
AnalystsBuy
Price Target$10.00(+651.88%)
Earnings DateMar 4, 2027

About ALT

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.

Address
910 Clopper Road, Gaithersburg, MD, 20878, US
Market Cap
259 million
Employees
57
Industrial Classification
Biotechnology

Altimmune, Inc. Stock Analysis — InsiderScore

Insider Score
See top-rated InsiderScore stocks ›
37th Percentile Overall Score
ALT InsiderScore:63 / 99

Altimmune, Inc. scored higher than 37% of companies evaluated by InsiderBuying, and ranked 50th out of 103 stocks in the biotech sector.

Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.

Dollars Committed

Insiders at Altimmune, Inc. bought $82.2K of stock across 3 purchases in the last 90 days, the largest of them $49.7K.

Stake Increase

The average purchase added about 28% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.

New Positions

Every buyer already held stock, so each purchase is an increase rather than a first position.

This category carries 35% of the Insider Score.

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$339.12K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
1 Buy0 Hold0 SellAvg target $6.25 (+369.9%)

1 firm rating ALT in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Weak
From ALT’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-5.67%
5 Days
-18.90%
1 Month
-40.36%
6 Months
-54.61%
1 Year
-72.35%

$ALT stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in ALT holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by ALT's directors and management

Net Shares Purchased by Insiders−70k−35k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

ALT Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New ALT patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to ALT from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in ALT

VTIVanguard Morningstar Total Stock Market ETF$9.24M
IWMiShares Russell 2000 ETF$7.04M
XBIState Street SPDR S&P Biotech ETF$6.43M
VXFVanguard Extended Market ETF$3.86M
IWNiShares Russell 2000 Value ETF$2.51M
VTWOVanguard Russell 2000 ETF$2.31M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from ALT’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
63.35
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
45

News check: Q3 earnings miss with funding concerns offset by analyst support and positive clinical data publication in MASH program.

Recent Insider Activity

Buys
10
Sells
0
Buy Value
$339.12K
Distinct Buyers
5

Insider Score Trend Over Time

+0.8 since Nov 14
0255075100Nov 14 — Insider Score 64.3Nov 15 — Insider Score 64.4Nov 16 — Insider Score 64.3Nov 17 — Insider Score 63.6Nov 18 — Insider Score 62.8Nov 19 — Insider Score 65.4Nov 20 — Insider Score 65.5Nov 21 — Insider Score 65.1Nov 14Nov 17Nov 21

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

BBCVirtus Biotech Clinical Trials ETF0.55%
PEPTREX Peptide ETF0.42%
QQQSInvesco NASDAQ Future Gen 200 ETF0.35%
SBIOALPS Medical Breakthroughs ETF0.20%
IWCiShares Micro-Cap ETF0.09%
XBIState Street SPDR S&P Biotech ETF0.07%
FESMFidelity Enhanced Small Cap ETF0.04%
FSEGFidelity Enhanced Small Cap Growth ETF0.03%
IBBiShares Biotechnology ETF0.02%
IBBQInvesco Nasdaq Biotechnology ETF0.02%
PWSPacer WealthShield ETF0.02%
LABUDirexion Daily S&P Biotech Bull 3X Shares0.02%

Weight is the stock’s share of each fund’s holdings.